<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<article xlink="http://www.w3.org/1999/xlink" dtd-version="1.0" article-type="neurology" lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher">JOHS</journal-id>
<journal-id journal-id-type="nlm-ta">Journ of Health Scien</journal-id>
<journal-title-group>
<journal-title>Journal of HealthCare Sciences</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Journ of Health Scien</abbrev-journal-title>
</journal-title-group>
<issn pub-type="ppub">2231-2196</issn>
<issn pub-type="opub">0975-5241</issn>
<publisher>
<publisher-name>Radiance Research Academy</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">89</article-id>
<article-id pub-id-type="doi">http://dx.doi.org/10.52533/JOHS.2022.21002 </article-id>
<article-id pub-id-type="doi-url"/>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Neurology</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Study of Safety and Effectiveness of Levodopa in Patients with Parkinson’s Disease
</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Ali</surname>
<given-names>Bayan</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fadel</surname>
<given-names>Emad</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Basilim</surname>
<given-names>Hani</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alsaeidi</surname>
<given-names>Omar</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Baraja</surname>
<given-names>Mervat</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Albishi</surname>
<given-names>Bandari</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Radi</surname>
<given-names>Zahra Al</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Assiri</surname>
<given-names>Mohammed</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Abusaif</surname>
<given-names>Mooza</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Aldebasi</surname>
<given-names>Iman</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Harshan</surname>
<given-names>Fahad</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alsalem</surname>
<given-names>Bayader</given-names>
</name>
</contrib>
</contrib-group>
<pub-date pub-type="ppub">
<day>30</day>
<month>11</month>
<year>-0001</year>
</pub-date>
<volume>2</volume>
<issue>10</issue>
<fpage>280</fpage>
<lpage>285</lpage>
<permissions>
<copyright-statement>This article is copyright of Popeye Publishing, 2009</copyright-statement>
<copyright-year>2009</copyright-year>
<license license-type="open-access" href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.</license-p>
</license>
</permissions>
<abstract>
<p>Parkinson__ampersandsign#39;s disease is the second most prevalent neurodegenerative disease in the world. Although there are no treatments that can inhibit the neurodegenerative process itself, symptomatic treatments can enhance patients__ampersandsign#39; quality of life. Dopamine replacement or augmentation treatments can partially or totally restore the dopaminergic neuronal degeneration that characterizes Parkinson__ampersandsign#39;s disease. Physicians most usually prescribe Levodopa, which is still the most potent oral dopaminergic medicine for Parkinson__ampersandsign#39;s disease. The purpose of this research is to review the available information about study of safety and effectiveness of levodopa in patients with Parkinson’s disease. Levodopa is the gold standard for the treatment of Parkinson’s disease since it is safe, effective and well tolerated among patients. It has been established that during the past 50 years the majority of Parkinson__ampersandsign#39;s symptoms improve in the average levodopa treated patient, most likely due to the striatal conversion of this amino acid into dopamine. Levodopa lessens morbidity and mortality, improves function and quality of life, and therefore lowers individual and community expenses. Levodopa, on the other hand, has a short half-life and is rapidly metabolized in the plasma, which results in variances, such as the wearing-off of action and uneven symptom relief as well as the onset of dyskinesias, both of which worsen as the disease progresses. Levodopa is often prescribed with other medications including carbidopa, pramipexole and others to lessen the side effects associated, further clinical research however can assist in developing strategies to make levodopa safer in long term use.
</p>
</abstract>
<kwd-group>
<kwd>Parkinson’s</kwd>
<kwd> disease</kwd>
<kwd> levodopa</kwd>
<kwd> safety</kwd>
</kwd-group>
</article-meta>
</front>
</article>